Cargando...
ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
Anemia is a well-known consequence of chronic kidney disease (CKD); it is mainly due to a relative insufficiency of erythropoietin synthesis by the failing kidneys. Over the years, the combination of erythropoiesis stimulating agents (ESA) and iron has become the standard of care of anemia. All ESAs...
Gardado en:
| Publicado en: | J Clin Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7922992/ https://ncbi.nlm.nih.gov/pubmed/33670704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10040839 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|